Repligen Corporation Q1 2026 Earnings Call - Strategic Reset Drives Margin Expansion and China Reacceleration

Casey Woodring, Analyst, J.P. Morgan3: Good day, ladies and gentlemen, welcome to Repligen Corporation’s first quarter 2026 earnings conference call. My name is Samantha, I will be your coordinator. Please note there will be a question and answer session following the company’s formal remarks. The company would like to note that there will be a limited timeframe for Q&A, and as such, management kindly requests that each individual ask 1 question to try to accommodate all. I will now turn the call over to your host for today’s call, Jacob Johnson, Vice President of Investor Relations for Repligen.

Jacob Johnson, Vice President of Investor Relations, Repligen Corporation: Thank you, operator, and welcome everyone to our 2026 1st quarter report. On this call, we will cover business highlights and financial performance for the 3-month period ended March 31st, 2026, and we’ll provide financial guidance for the full year 2026. Joining us on the call today are Repligen’s President and Chief Executive Officer, Olivier Loeillot, and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ.

Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, our current reports, including the Form 8-K that we are filing today, and other filings that we make with the Securities and Exchange Commission. Today’s comments reflect management’s current views, which could change as a result of new information, future events, or otherwise. The company does not oblige or commit itself to update forward-looking statements except as required by law. During this call, we are providing non-GAAP financial results and guidance unless otherwise noted. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen’s website and on sec.gov.

Adjusted non-GAAP figures in today’s report include the following: organic revenue and/or revenue growth, cost of goods sold, gross profit and gross margin, operating expenses, including R&D and SG&A, income from operations and operating margin, other income or expense, tax rate on pre-tax income, net income, diluted earnings per share, EBITDA, adjusted EBITDA, and adjusted EBITDA margin. These adjusted financial measures should not be viewed as an alternative to GAAP measures but are intended to best reflect the performance of our ongoing operations. With that, I’ll turn the call over to Olivier.

Casey Woodring, Analyst, J.P. Morgan2: Thank you, Jacob. Good morning, everyone, welcome to our 2026 first quarter call. We are delighted to share our first quarter 2026 results. Great execution once again by our team enabled us to deliver 15% reported revenue growth or 11% organic and 160 basis points of adjusted operating margin expansion. Mid-teens top-line growth, coupled with disciplined cost management, resulted in margins outperforming expectations. In addition to our strong financial performance in the quarter, we advanced several key strategic priorities. This includes the launch of our transformation office, the associated sale of the Polymem business, and a new partnership in China. This OEM relationship advances our strategy in the country where we are seeing significant growth again. I’ll touch on each of these initiatives in more detail shortly.

As I reflect on our end markets and company today, it’s encouraging to see the strength we’re seeing across all of our customer segments. The talented and experienced team we have assembled is executing fiercely on our differentiated strategy. This has resulted in a very rich, high-probability opportunity funnel that just needs to be coupled with faster customer decision-making. We did see encouraging signs in the first quarter and remain convinced the capital equipment tap will open. We delivered $194 million of first quarter revenue, driven by healthy demand across our broad portfolio and all geographies. Analytics led the way with 50%+ growth, but all of our franchises grew nicely again in the first quarter. Consumables, including proteins, grew double digits, which was coupled with solid capital equipment growth, and services remained a standout with 30%+ growth.

Capital equipment demand benefited from strength in analytics, mixers, and easier comps. We also saw growth across our diversified customer base and all geographies. Order trends were solid in the first quarter with a significant pickup in March and included some conversion of our robust capital equipment funnel. Our first quarter results and these recent order trends reinforce our confidence in our full-year revenue outlook. Jason will provide more details. We are reiterating our expectation for 9%-13% organic growth while updating our reported revenue guidance to reflect the sale of our non-core and low-margin Polymem business. This reduces our full-year revenue outlook by $7 million but improves our margin outlook. In addition, given our strong first quarter performance, we are increasing our adjusted earnings per share guidance for the full year.

We remain excited about our differentiated product portfolio, the global team we’ve built, and the strategy we’re executing. As we look ahead to the next several years, we see a number of opportunities across our portfolio that position us for robust growth and allow us to continue to outpace the market. Looking at our performance by end market, we saw widespread strength across our customer base. CDMO revenues grew mid-teens, with similar growth across both tier 1 and tier 2. Biopharma revenues also grew despite a very difficult comparison. We saw notable growth outside of large pharma, including 20% plus growth from emerging biotechs. We continue to be encouraged by growth from this customer base, though demand remains below historical levels. OEM and integrator demand was very robust, given growth in fluid management. From a geographic point of view, we saw strengths across all regions led by Asia Pacific.

This included a near doubling of revenues in China with our best revenue quarter in the country in over two years. This is a testament to the team we’ve put in place. Asia Pacific remains a key strategic region, and I will discuss the progress on our strategy in China shortly. As expected, new modalities were dilutive to growth, given the gene therapy headwind we previously discussed. We continue to see healthy growth in cell therapy and also in gene therapy when excluding that specific headwind. I wanted to update you on the following three strategic initiatives. First, as we have emphasized recently, we are committed to expanding margins while balancing the efforts needed to support future growth.

In an effort to accelerate both of our Fit for Growth journey and our path to 30% adjusted EBITDA margin by 2030, we have formed a transformation office that will ensure we have the right prioritization and resources focused on these critical initiatives. Key focus areas under this program include efforts to optimize our manufacturing footprint for increased cost efficiency, improving the profitability of certain product lines through targeted productivity and rationalization, continuously improving service to our customers, and efforts to capture the value of our differentiated products, and finally, acceleration of our IT modernization and AI implementation across all functions. Jason will walk you through more details, but in terms of financial impact, we estimate this effort should result in at least 1 point of annualized margin benefit by the end of 2027.

We remain committed to our goal of doubling the business and expanding margin while further progressing our Fit for Growth capabilities. The transformation office will enable us to achieve and accelerate all of this. Most of these initiatives have just kicked off. We’re happy to share that as part of this effort, on March 30th, we divested the Polymem operation in France for nominal proceeds. While this facility was a key contributor to Repligen’s ability to supply product during the pandemic, the business has since reverted to non-core sales outside bioprocessing and has operated at a net loss. In 2025, Polymem generated $7 million of revenue and an adjusted operating loss. The new owner will offer synergies in the common market in which they operate. Second, we remain more excited than ever by our growth opportunity in Asia.

In fact, Jason and I recently returned from a week-long visit to the region where we met with both key customers and our Asia leadership team. We are building a great team and continuing to gain traction with key customers in the region. We are also thrilled to announce that while in the region, we signed a critical partnership to expand our capabilities and local presence in China. The partnership outlines an OEM relationship that will increase our competitiveness and access to local manufacturing beginning in 2027. It will be a multi-phase and multi-product arrangement that we expect to expand over the coming years. After our trip, we are more conviction than ever that China will be a meaningful player in biopharma for years to come. Finally, I want to comment on our IT investments and digitization journey.

On our last call, we mentioned investment in our IT organization in 2026 as part of our Fit for Growth journey. We have made key additions to our team this year, including new data management and AI experts. We have implemented AI across a variety of functions, including, but not limited to legal, commercial, and supply chain. As part of our transformation office, we are also working to further optimize our data infrastructure, which will allow us to better implement AI in the coming years. To support our customers, our analytics franchise is well-positioned for an increasingly digital environment. Our PAT product portfolio allows for the collection of both upstream and downstream data in real time. We have integrated our FlowVPX into our downstream filtration system and are working to replicate this on the upstream side.

We announced a partnership with Novasign last year and are working to integrate their digital twin capabilities into our next-generation small-scale filtration systems. We see digitization as a multi-year journey, and it remains a key strategic focus area for our company. Before I turn the call over to Jason, I’ll provide some more detail on our franchise-level performance. Starting with filtration. Revenue grew mid-single digits on a reported basis in the quarter, driven by fluid management, ATF, and other consumables. Excluding the gene therapy headwind, this franchise would have delivered double-digit growth. With the sale of Polymem, we now expect filtration growth to be roughly mid-single digits in 2026 on a reported basis. This also contemplates a moderated ATF outlook in 2026 due to customer-specific timing dynamics that are expected to be a tailwind in 2027.

A result, we see ATF returning to strong growth in 2027 and beyond. We continue to see overall healthy consumable demand across our portfolio. We remain extremely confident in our process intensification leadership position. After over a decade of seeding our ATF technology, we have built a high amount of trust from the biopharma industry. We will continue to prioritize further innovation and advancements that will allow us to remain the industry’s partner in process intensification. Chromatography revenue increased over 25%, driven by growth in OPUS columns. We continue to win new customers globally as they appreciate the plug-and-play convenience of pre-packed columns. Given the traction we are seeing in OPUS, we now expect 20%+ growth in chromatography in 2026. With this outlook, we do expect a slightly higher mix of chromatography revenue versus our initial expectations.

It was a great quarter in proteins with mid-teens growth on top of a very strong prior year comparison. We saw healthy demand across our offerings led by our ligands, reflecting the benefits of the strategy we put in place to control our own destiny in proteins. We expect protein growth of at least low double digits for the year. Our analytics franchise had another phenomenal quarter with 50%+ growth. This was led by notable strength in our downstream analytics offering, which had a record quarter. This benefited from strong demand for our SoloVPE PLUS, including new placements and upgrades. We continue to assume analytics growth of 20%+, given momentum in downstream demand and a growing contribution throughout the year from our upstream analytics offering. To wrap up, we are very pleased with our start to 2026.

We delivered 11% organic growth in the first quarter, which is right in line with the midpoint of our full-year guidance. This, coupled with operating expense discipline, has reinforced our confidence in our full-year revenue outlook and enabled us to increase our adjusted earnings per share guidance. In addition, we made tangible progress on our strategic priorities, which positions us well to drive robust growth and margin expansion in coming years. Now, I turn the call over to Jason for the financial highlights.

Jason Garland, Chief Financial Officer, Repligen Corporation: Thank you, Olivier, and good morning, everyone. Today, we are reporting our financial results for the first quarter of 2026 and providing updated guidance for the full year 2026. Unless otherwise noted, all financial measures discussed reflect adjusted non-GAAP measures. As shared in our press release this morning, we delivered first quarter revenue of $194 million, a reported year-over-year increase of 15%. This is an 11% organic growth, excluding the impact of acquisitions and foreign exchange. Foreign currency contributed 3 points of growth, and we had 2 months of inorganic contribution from our upstream analytics acquisition. As Olivier offered details on our product franchise performance, I’ll provide more color on our regional performance.

Starting with quarterly revenue mix, North America represented approximately 46% of our total, EMEA represented 37%, and Asia Pacific and the rest of the world represented approximately 17%. North America grew mid-single digits, driven by OPUS and analytics. EMEA grew more than 20%, driven by proteins and OPUS. Asia Pacific grew more than 25%, driven by ATFs, mixers, and analytics. As previously mentioned, we had very strong growth in China. Transitioning to profit and margins, first quarter adjusted gross profit was $108 million, and adjusted gross margin was 55.5%. This was 180 basis points of margin expansion versus last year. The year-over-year increase was driven primarily by volume leverage, pricing execution, and favorable product mix, all of which more than offset inflation and tariffs.

The favorable mix was driven by growth in our analytics business and certain accretive filtration products. In addition, first quarter gross margin also benefited from cost absorption timing associated with production levels required to support the sales ramp through the year. We expect this benefit to normalize over the remainder of 2026. Continuing through the P&L, our adjusted income from operations was $30 million in the first quarter, up 28% year-over-year on a reported and organic basis. OpEx grew 11% on an organic basis. We remain thoughtful about balancing investments in the business while expanding margin.

We expect some additional investment in the second quarter. This translated to an adjusted operating margin of 15.4% in the first quarter, which was an increase of 160 basis points year-over-year on a reported basis, and 200 basis points of margin expansion excluding M&A and the impact of foreign currency. Adjusted EBITDA was $40 million in the quarter, or just under 21% adjusted EBITDA margin. Moving to the bottom line, adjusted net income was $27 million, a 22% year-over-year increase. Higher adjusted operating income was offset by slightly lower interest income on declining interest rates. Our first quarter adjusted effective tax rate was 22%, which starts the year on the low end of our full year guidance, which remains unchanged.

Adjusted fully diluted earnings per share for the first quarter was $0.48 compared to $0.39 in the same period in 2025, or an increase of 23%. Finally, our cash and marketable securities position at the end of the first quarter was $785 million, up $17 million sequentially from the fourth quarter. This was driven by $28 million of strong cash flow from operations, offset by $5 million of CapEx in the quarter. We remain focused on optimizing our working capital to drive improved cash flow conversion. I will now speak to adjusted financial guidance. As Olivier mentioned, we are reiterating our organic growth guidance for full year 2026, while updating guidance for the sale of Polymem and our first quarter results.

Our guidance also assumes a couple million dollars of tariff surcharges in 2026. We are now guiding $803 million-$833 million of revenue, or 9%-13% growth on both a reported and organic basis. Our update in guidance now reflects only 1 quarter of revenue from Polymem, which removes approximately $7 million of revenue from the full year previously included in guidance. This continues to assume just under a point of benefit from foreign currency, which we realized in the first quarter. Our reported growth of 9%-13% assumes the following: mid-single-digit growth in filtration, greater than 20% growth in chromatography, proteins growth greater than low double digits, and 20%+ growth in analytics.

We now expect 110-160 basis points of gross margin expansion for the year. This assumes a slight benefit from the divestiture, partially offset by higher chromatography mix and limited impact from the conflict in the Middle East. With the strong Q1 performance, the sale of Polymem, and judicious management of OpEx, we are raising our adjusted income guidance. We now expect $124 million-$132 million of adjusted operating income. This implies 160-200 basis points of operating margin expansion, which represents a 30 basis point increase at the midpoint versus our prior guidance. Continuing through the P&L, we now assume $90 million of adjusted other income and continue to assume a 22%-23% adjusted effective tax rate.

Putting this together, we expect adjusted fully diluted earnings per share to be between $1.97 and $2.05. This is up $0.26-$0.34 versus 2025, or up 18% at the midpoint, and $0.04 higher than our prior guidance at both the low and high ends of the range. To assist with the quarterly cadence, we expect Q2 organic revenue growth to be similar to the first quarter. As a result, our guidance does not require a second half acceleration to achieve the midpoint of our full year outlook. We expect second quarter gross margin to be slightly below our full year guidance range and OpEx to pick up slightly sequentially following our disciplined OpEx control in the first quarter. We expect second half OpEx to be similar to 2Q.

As a result, we expect solid operating margin expansion in the second quarter, while the third quarter will likely represent the lowest margin quarter of the year. Our balance sheet remained strong as we ended the first quarter with $785 million of cash and marketable securities. We will remain prudent in our spending while maintaining substantial dry powder for potential acquisitions. We expect CapEx spend to be approximately 3%-4% of 2026 revenue. Before we wrap, I wanted to briefly follow up on the transformation office that Olivier shared earlier. We are thrilled to establish a team of both internal and external experts to drive focused improvements in areas that will drive our Fit for Growth capabilities and margin expansion. This is a change in mindset that reinforces the structured framework is required to drive margin expansion beyond volume leverage.

As Olivier shared, we expect to see meaningful benefits from the initiatives. We are still finalizing the detailed scopes and benefits, expect to generate at least one point of annualized margin benefit by the end of next year and continue into 2028 and beyond. We will see benefits in both gross margin and at the EBIT and EBITDA level. We see this effort accelerating our path to our 2030 EBITDA target. In other words, our path to reaching 30% adjusted EBITDA margins will be less weighted to the out years than previously communicated. We expect non-recurring charges of approximately $5 million-$6 million through 2027 associated with this effort. These will be excluded from our adjusted non-GAAP results. Finally, Olivier and I would like to thank our Repligen teammates for delivering a strong start to 2026.

We continue to be energized by the opportunities ahead, and we are focused on advancing our strategic efforts in 2026. With that, I’ll turn the call back to the operator to open the line for questions.

Casey Woodring, Analyst, J.P. Morgan3: We will now begin the question-and-answer session. Please limit yourself to one question. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Dan Arias with Stifel. Dan, your line is open. Please go ahead.

Dan Arias, Analyst, Stifel: Hey, good morning, guys. Thank you. Jason, nice start to the year on the op margins there. Obviously, you went through some of the moving parts, but can you just maybe summarize what within the quarter was sort of incidental, I guess you could call it, mixed elements, timing of cost items, versus more of a reprioritization that sounds like maybe is starting to be in play here? Along those lines, like the transformation office impact.

I know you said you’re still working through the moving parts there, but is the right way to think about that the normal 100-200 basis points of annual op margin expansion that you’ve been talking about plus the impact of transformation, you know, and is that like 100 basis points to FY 2027, or are you kind of run rating, you know, by the time you get to the year, at the end of the year at 100 basis points? I just want to make sure that we get the modeling element of that whole exercise right.

Casey Woodring, Analyst, J.P. Morgan2: Hey, Dan. Good morning. Olivier here. I’m just gonna kick it off and then let Jason give you more details. I mean, we’re obviously extremely happy about how we delivered on the, on margin expansion in quarter 1, but beyond quarter 1, obviously being able also to have line of sight of further improvement over the rest of the year as well. Yes, you’re right, the transformation office is an initiative like we’ve been thinking about for a long period of time. Now that we have the right people on board, we said that’s the right time to kick it off. As you’ll hear from Jason in a few second, it’s really a mix of getting acceleration on the Fit for Growth side, but also accelerating margin improvement. Jason, yeah.

Jason Garland, Chief Financial Officer, Repligen Corporation: Yeah. Dan, great free question. A lot of pieces in there. We’ll go through it. Yeah, really happy with the first quarter gross margin and overall margin performance. You know, I think to your question, the driver really was volume leverage price. Continuing to execute that. To your point, strong mix really from analytics growth as well as a few of the, I’ll say, product lines within our overall filtration franchise. There was a timing element to your point on a little bit from timing of cost absorption that will unwind through the year. Overall, it sets us up for, you know, well and high confidence in our guide for expanding gross margin by about 110 to 160 basis points for the year.

From a profile perspective, yeah, we do expect 2Q to be lower than 1Q. You know, 3Q may step down slightly from that as well, fourth quarter back, you know, higher as we, you know, grow on volumes through the end of the year. Most of that change will be driven by the mix phasing. Here’s what I’d say, though. On a total year versus a total year or full year versus full year basis year over year, mix is still a neutral dynamic for us. For the first quarter being positive, we’ll see some mix headwinds in the second and third, you know, again, fourth quarter steps back up, mostly on higher chromatography sales. To your point, again, that cost absorption unwind.

Again, a real great start, and it puts us right on track to our guide. Lifted it up a little bit with Polymem. On the transformation office, yeah, again, great questions as well. Look, I’ll start by, you know, it’s really about creating this structured program where we allocate the right resources to our priorities. There’s a real heavy Fit for Growth execution and developing the capabilities we need and then the margin expansion side. That 1 point of annualized margin expansion by end of 2027, think of that as more in the run rate. You know, we’ll have various elements and projects that will, you know, I’ll say, come into initiation over several months, right?

We haven’t assumed anything in 2026 yet, there may be, you know, some benefits that we’ll share later in the year if they come in early. We’re really expecting a run rate to start, you know, by the end of 2027 and then kind of seeing full benefits in 2028. To your point, that’s gonna be on top of our normal run rate, that was the message that we tried to share in here as well. Again, we’ve talked a lot about this path to 30% EBITDA target by 2030, that we would be more weighted toward the back end. We think this initiative helps us to be less weighted in those out years, which brings some incremental in the early years. I’m really excited about all this. Great start to the year.

Dan Arias, Analyst, Stifel: Okay. Super. Thank you.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Doug Schenkel with Wolfe Research. Doug, your line is open. Please go ahead.

Madeleine Nolan, Analyst, Wolfe Research: Hi, this is Madeleine Nolan on for Doug. Just a question on equipment. You mentioned that there was a pickup in equipment in March. Where was the strength most notable? Was it by category and customer type? Did that help you in the quarter, or was it more the order book? I think last quarter you mentioned that there were some RFPs you were waiting on. Have you started to hear back on those, or do you feel that pharma companies are still digesting some of the MFN deals? Thank you.

Casey Woodring, Analyst, J.P. Morgan2: Good morning, Madeleine, good questions. Capital equipment increased year-over-year in quarter 1 on what was pretty easy comp, to be very open, and that was mostly driven by strength in both analytics and mixers as well. We’ve partly seen a nice pickup of mixer demand in China, which is 1 of the reason why China did so well for us in quarter 1. Similar to P&L as well, we’ve seen orders increasing in the quarter. After what was maybe a bit of a slower start in January up to mid of February, we’ve seen a real acceleration of ordering take toward the second half of the quarter, and particularly on the capital equipment side.

We realize pharma’s still taking their time, but it was good to see indeed, finally some answers coming, and positive answers. To your last point on RFP win, yes, we start to win some of the RFP. We answered 2 towards the end of last year, which is, for us, very encouraging because as I mentioned previously, we didn’t really have a seat at the table before. Overall, very encouraging and we would like to see further acceleration of decision-making, but definitely going in the right direction right now.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Matthew Larew with William Blair. Matt, your line is open. Please go ahead.

Casey Woodring, Analyst, J.P. Morgan0: Hi, good morning. You called out 20% growth from emerging biotech, that comes off at, you know, three very strong quarters to end 2025. You did reference it’s still below historical levels. We’re now working off the back of two straight quarters of strong funding data. There’s been some positive clinical updates. You’re gonna be escaping the one large customer headwind. Olivier Loeillot, I’d just be curious for your take on sort of what’s remaining to get emerging biotech back to strength and how you feel about the momentum there the last couple quarters.

Casey Woodring, Analyst, J.P. Morgan2: Good morning, Matthew Hewitt. Obviously very happy to see the 4th quarter in a row of very significant growth for that customer segment. I mean, as I’ve said, like, we’ve seen each of these segment coming back 1 after the other, and that was the last 1. To be still fair, I mean, Q1 comp were pretty easy still, so I want to see Q2 still showing exactly the same growth. Overall, it sounds like this market segment is back to a much more normal type of behavior. You’re right, the customer, the biotech funding numbers also look very good. I mean, Q1 was almost double what it was last year, April was very strong. I mean, I think I’ve seen numbers around $10 billion funding in April.

The good news is we’ve seen really a nice rebound. We’re still of the opinion that the money that has been injected has not reached yet all of these guys fully to the extent that they are spending much more money. To your point, yes, what we’ve seen should hopefully be very sustainable, and we’re hoping to see a similar type of growth over the next few quarters for emerging biotech. Definitely something that we’re very excited about. Fourth quarter in a row, very nice growth here.

Casey Woodring, Analyst, J.P. Morgan0: Okay, thank you.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Philip Song with Leerink Partners. Philip, your line is open. Please go ahead.

Casey Woodring, Analyst, J.P. Morgan5: Question. This is Philip Song for Puneet. You mentioned China nearly doubled in Q1. This is off a low base after just 2 quarters of growth in the second half, and I think 2%-3% revenue contribution. I was wondering if you could just unpack this some more, just how much impact was from the OEM partnership, kind of what was the composition between large pharma and CDMOs, and I guess, how would you characterize how much was order timing versus sort of genuine demand acceleration? Thank you.

Casey Woodring, Analyst, J.P. Morgan2: Good morning, Philip. Absolutely delighted about the way quarter one played out for us in China. I mean, you’ve heard me talking about it quite a lot over the last several quarters, and it was absolutely awesome to almost hear doubling of our sales in China in quarter one. You’re right, it was on very low comp. What I’m even more excited about, to be honest, is our funnel looks really very strong. I mean, Jason and I were in the region recently. We spent almost a week with the team down there, and we’re seeing a funnel that looks really very strong across all of China right now, and that’s very exciting. By the way, talking about China, all of Asia did very well.

I mean, that was our fastest growing market geographically in quarter one. Obviously to your question about the OEM partner, I mean, this has no impact yet. I mean, we literally just signed the agreement a couple of weeks ago, so we’re gonna transfer different part of our portfolio, particularly on the filtration consumable side, and we expect those guys, those partner to be up and running probably towards the beginning of next year. It’s never really black and white, and where you’re somewhat probably clear asking the question is it’s a good strong signal we’re giving to customer in China that we are back, and that we’re gonna really reclaim our market in China with that partner.

Also we really want to be part of that huge upcoming market growth we’re seeing in China over the next several years. There might be already a little impact that people feel like, wow, Repligen is going to become really a very strong actor in China for China, and that’s why we’re delighted about that agreement. It is just a first step, Philip. I mean, we are looking at expanding that collaboration and potentially with other partners as well in China over the next several years. Very excited to be back in China.

Casey Woodring, Analyst, J.P. Morgan5: Thank you.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Casey Woodring with J.P. Morgan. Casey, your line is open. Please go ahead.

Casey Woodring, Analyst, J.P. Morgan: Great. Thank you for taking my questions. You had a 1 point organic beat in Q1 and expect similar growth in Q2, but you kept the low end of the full year guide unchanged. Maybe just talk about how much of that is driven by the moderated view for ATF in the second half versus the rest of the business. Then on ATF, you know, could you provide more color on the customer timing dynamics that are driving that more moderated view in the second half? I think in the past you had talked about a second half ramp in ATF consumables tied to one of the blockbusters that you expect in 2. Is that really just a function of a customer delaying commercial launch? Then, you know, what gives you confidence that things will pick up in 2027? Thank you.

Casey Woodring, Analyst, J.P. Morgan2: Yes. Good morning, Casey. First of all, I mean, we’re obviously very happy we started quarter one at the midpoint of our full year guidance. As you heard us saying, we estimate quarter two will probably be about the same. Obviously it will set us up very well for the guidance we’ve given at the beginning of the year. The midpoint would assume at this stage, like there is no need for any acceleration toward the second half of this year, which is probably a little bit of a Repligen specific situation that we’re very happy to be in right now. It’s a really high comfort zone for us from that point of view.

We would be disappointed if we would land at the low end, because that would somehow imply a softening of the market that we’re actually not seeing today. We’re more hopefully looking at to reach the high end. In order to reach the high end, we would need some type of acceleration both of our consumable business, and you mentioned ATF, I’ll come back to that in 10 seconds, but also that some of these equipment orders we’ve been receiving now in the last couple of months would also be potentially delivered this year, which is not a given yet because we need to hear about our customer side preparedness to be able to accommodate that or not. That’s kind of really the way to look at the guidance for this year.

We are quartering to the year with a very strong start, with couple more quarters, we’ll know much more about how the year is gonna play out by the end of July when we report out on quarter 2. In term of ATF, yes. I mean, we have always been very transparent. I mean, we were transparent last year about what happened with that specific gene therapy program. We said we’re gonna be transparent. ATF has got a huge runway for the next several years. I mean, I can tell you we’re more bullish than ever. A couple of our customers came to us beginning of this year explaining as they were managing inventory this year on a couple of commercial drugs that have been using ATF now for a few years.

This is not something unusual for what is still a pretty new technology where at the beginning, people built a little bit more stock maybe than they will need finally. We know it’s gonna be a real tailwind for us from 27 onwards because these are two commercial drugs that will require more because the drugs themselves are growing very nicely. It’s really just a temporary inventory management that we’re facing. What’s interesting about those two customers is, in fact, they are implementing ATF across many more products than this specific commercial drug I was talking about, which is why we know next year it’s gonna be a real tailwind for these customers for the commercial drugs themselves, but also across the new ones they are implementing ATF at right now.

Casey Woodring, Analyst, J.P. Morgan: Great. That’s super helpful. Thank you.

Casey Woodring, Analyst, J.P. Morgan2: Thanks, Casey.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Daniel Markowitz with Evercore. Daniel, your line is open. Please go ahead.

Daniel Markowitz, Analyst, Evercore: I wanted to follow up on emerging biotech. It’s good to see 4 quarters in a row, if I heard correctly, of growth from this customer segment. I wanted to talk about the benefit from biotech funding recovery, which seems like it could flow through to back half of this year and help in back half in 2027. Can you help frame the potential timing of when this benefit might occur? Remind us your exposure to this customer set, and help us understand what the contribution could look like once we start to see that benefit.

Casey Woodring, Analyst, J.P. Morgan2: Yeah. No, good morning, Dan. I think yeah, you nailed it already pretty well. I mean, 4 quarter in a row of very significant growth. I mean, I would say very significant growth in quarter one was above 20% of growth. This being said, the activity level still remains slightly below historical level. That’s why we’re saying it’s probably a little bit too soon to call it a trend. Maybe to be a more bit more specific, we mentioned in previous call, like we’ve seen some of the growth coming from some of these small Biotech getting acquired. That was particularly the case in quarter 2, quarter 3 of last year.

It’s fair to assume that some of the funding that we started to improve towards quarter three of last year has maybe started to reach some of these companies toward the end of last year and probably a little bit more in quarter one. I do expect it to become a real stronger tailwind from quarter two, quarter three onwards to be confirmed, but that’s what we could expect, we would expect looking at this much better biotech funding environment we’ve been experiencing. To answer your specific question, I mean, it’s still low-lower than 10% of our total sales.

I want to say probably more into the 8%-9% vicinity in quarter one, but probably trending back to the 10% that we experienced in the past in the next few quarters, I would imagine. Yeah.

Daniel Markowitz, Analyst, Evercore: That’s helpful. Then just a follow-up. Can you talk about the ATF opportunity more broadly? Like, how penetrated is this market, and how would you frame the potential impact from competitive product introductions?

Casey Woodring, Analyst, J.P. Morgan2: I mean, again, maybe let me start by saying ATF grew in quarter one, both by the way, in capital and consumable as well. We’ve just decided to moderate our expectation for 2026 because of this transitory headwind that we’ve been hearing from the two specific customers. Apart from that, I mean, we are still extremely bullish. I mean, we were getting our product designing in multiple new products, multiple new modality as well. I mean, we’ve talked about the successes we’ve had on the cell therapy side, that has become a very significant tailwind for us over the last several quarters. We are also very heavy on innovation.

I tell you, I’m very, very confident about the fact, we were going to be leading the process intensification for the next several years. I mean, I have zero doubt about that. We’ve got a lot of innovation being worked out right now with several launches that we expect to happen probably toward the beginning of next year and then one or two others toward mid or end of next year. We are absolutely very bullish, and the runway on ATF is still absolutely very strong, yeah. Great. Thank you very much.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Mac Etoch with Stephens. Mac, your line is open.

Mac Etoch, Analyst, Stephens: Hey.

Casey Woodring, Analyst, J.P. Morgan3: Please go ahead.

Mac Etoch, Analyst, Stephens: Hey, good morning. Thank you for taking my questions. Maybe just following up on some of the previous order-related questions, just looking at what you called out during March, can you just unpack what specifically changed in the order environment at that point? Was it tied to improving customer decision-making, budget releases, increased activity within certain end markets like, you know, maybe analytics or upstream systems? How is that exit rate carrying April at this point?

Casey Woodring, Analyst, J.P. Morgan2: Hey, Mac. Good morning. It’s a little bit of all of that, to be honest with you, but maybe let me take one step back, yeah. You’re right. I mean, we had a little bit of taking 2 steps back first. We had a fantastic quarter for in terms of order intake, and I really wanna say fantastic. I mean, it was like in years we had not seen like for probably the previous several years and so on. It was somehow pretty expectable that the beginning of quarter one would be a little bit softer.

Towards middle of February, we started to see a really significant acceleration that has enabled us to deliver very strong order intake for the full quarter one, really in the right ZIP code in term of book-to-bill, like what we expect for the previous several quarters. Really across the board, very healthy quarter one, thanks to what happened in March. What’s more important, honestly, than order, because we’ve said it can be somewhat a little bit lumpy. As you know, we’re tracking our funnel, and I want to say we are really extraordinarily disciplined on the way we’re tracking our funnel.

One part of our, the funnel I’m looking at myself on a weekly basis is what we call the high probability funnel, which is a probability that is above 50% of closing orders within the next 2 to 3 quarters. I mean, that funnel of high probability is at the highest level ever. In fact, I just made the exercise a week or 2 ago, looking at how did it look versus where it looked like a year ago, and it’s significantly higher than what we’ve sort of seen a year ago. From that point of view, we are very confident about the way things are gonna play out for the next several quarters.

What we are not still controlling fully is decision-making, and that’s maybe where indeed I would still see a bit of a difference between a consumable and equipment. Both look really good for this year. I mean, in term of guidance for the full year, we see like both were growing double-digit in sales. Obviously, most of the headwind we’ve talked about are going into consumable, as you know, meaning the gene therapy program on one side and then these 2 ATF customers on the other side. It means like consumable are still doing extremely well. On capital equipment, it’s fair to say like analytics and mixers have been leading the pack. We would like to see a real acceleration of what we call the bigger type of CapEx equipment.

We started to win some of these RFPs. As I mentioned earlier, if the tap of capital equipment really opens, this is gonna be a massive opportunity for all of us. I say massive because I think the water is just waiting for the tap to open, and then it’s gonna become like a totally different story for all tool providers. That’s kind of really a long answer to a short question, but that’s across the board how we’re seeing order intake and how we’re seeing the different part of the business between consumable and hardware.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Paul Knight with KeyBank. Paul, your line is open. Please go ahead.

Casey Woodring, Analyst, J.P. Morgan4: Yeah. Thank you. Congrats on the quarter. When you look at the China market right now, is this domestic demand or is it multinationals expanding their bioprocess capabilities in that market?

Casey Woodring, Analyst, J.P. Morgan2: Good morning, Paul. I have to say at this stage, the vast majority, and I say vast majority, at least what I have a good line of sight of, is really China local demand market that’s coming back. We’ve had really a lot of successes. I mentioned mixers already 2 times. Beyond mixers, even on our filters, consumable and so on, we are seeing a lot of these customers coming back now.

As you know very well, we Paul, we are facing much more competition than we were before, which is why we’ve been pushing and now implementing that strategy that I think is very different, very differentiating as well, versus what others might have been doing, where we are really gonna capitalize on local company to help us gaining our market back, yeah. I’ve said several times, the China market today is totally different than it was, 5 years ago, even maybe, 3 years ago. Even to a certain extent, if you want to succeed in China, you have to appear to be much more really Chinese than you were before, that the only way you’re gonna be able to defeat competition locally.

We found a partner that we like a lot because we know the management team pretty well. Also, they are still in the early phase of growth. I’ve seen so many of these company being successful over the last several years that collaborating together, we feel we have got an incredible runway over the next several years. The demand is really from Chinese company for Chinese local demand, which we know is going to grow very significantly over the next several years now with all of the money that has been injected into the China ecosystem. Thank you.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Brendan Smith with TD Cowen. Brendan, your line is open. Please go ahead.

Brendan Smith, Analyst, TD Cowen: Great. Thanks for taking the questions, guys. Congrats on the quarter. Wanted to actually ask just another one on the transformation office a bit. Any more granularity on what kinds of margin optimization efforts you really have going on there? I guess, are you focused on certain segments more than others? I know you mentioned some AI process involvement. I guess just wondering if there’s any potential for some of the relative margins across your different segments to maybe close ranks a bit from some of the historical spread we’ve seen. Thanks.

Jason Garland, Chief Financial Officer, Repligen Corporation: Yeah, no, Brendan, good question. You know, we highlighted kind of 4 buckets. One is manufacturing footprint in terms of how to optimize that. That, of course, will hit either different product lines or help us drive efficiencies across the overall network. The other piece to your point is really this improving profitability on certain product lines. You know, these examples of where do we look at our portfolio? What’s dilutive to the overall average? How can we look at design changes? How can we look at manufacturing efficiencies? To your point, how do we look at the product SKUs that we have to try to raise that overall?

It’s things like Polymem again, where we saw that as a non-core product, not even within bioprocessing, not only dilutive at the margin, but a loss at the bottom line. You know, that was fairly unique though, you know. It’s absolutely about finding the below margin products and then increasing those. The other piece is also around how do we serve our customers better, how do we get more value. Again, you might see that within the product lines. The other big bucket is this topic of IT modernization as well as AI, and we kind of keep them connected, but also have very different paths on each of those.

We’ve talked a lot about the need to upgrade our IT infrastructure. It’s data, you know. I’ll say optimization. When you look at the number of applications and vendors we have for our size company, we can rationalize that. That’s the type of thing that actually drives synergies and cost savings. As well as bring, how do we leverage SAP, you know, our ERP as well to get more out of that. From an AI perspective, it’s this balance of, you know, looking at the tools that are available, but then also going back into each process and function and understanding the problems that we’re solving and the use cases for that, those AI, you know, I’ll say solutions. Incredibly exciting for us.

Again, this is about allocating the right resources, you know, focusing internal experts as well as bringing external experts to help us accelerate that. Again, it’s just another example of kind of the long game that we’re playing on both, margin expansion as well as being able to grow and scale.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Matthew Stanton with Jefferies. Matt, your line is open. Please go ahead.

Casey Woodring, Analyst, J.P. Morgan2: Thanks. Maybe just one in the context of the order commentary and then the kind of high probability funnel you laid out, Olivier. Could you just remind us in terms of your equipment portfolio and the order book there, how quickly you turn that? I think historically you had kind of talked about earning two-thirds of the order book in six months or less. I think it would be helpful to kind of get an updated number on that given the evolution of the portfolio, you know, as it relates about what could maybe show up in orders today and in common revenues in the back half of the year versus 2027. It sounds like mixers, you know, analytics, some of those are maybe shorter cycle type equipment than the larger projects you talked about, Olivier.

Would just be helpful to kind of level set the order book, how quickly you think you can turn that today and, you know, how that maybe has evolved from a couple years ago. Thanks. Hey, good morning, Matt. Yeah. I think you answered your question very well, so I’ll try to add some more details here. You’re absolutely right. Like, we’ve got very different type of hardware in our portfolio. The two you mentioned, you’re right. Both mixers on the one side and analytics on the other side, turnaround time is very short. I mean, in fact, for analytics, typically, you can even turn around an order within a couple of weeks or so.

For mixer, here I would differentiate what we call the stainless steel mixers, which is what we acquired when we acquired Metenova 2 and a half years ago from the single-use mixers. Lead time are slightly different. For the stainless steel side, we are like below 3 months. For the single-use mixer, we would probably be a little bit more than 3 months. There is a slight difference here. Well, even within the larger scale type of hardware, there is still a difference. For ATF, the ATF system, very often we are capable to turn around delivery in 3 months or even less sometime, if we’ve got no customization to achieve.

For downstream system, whether TFF or chrom system, it really depends again whether it’s catalog type of product or whether it requires some customization. If it’s catalog, turnaround time can also be in the range of 3 months or so. If it’s custom, probably more into the 5 to 6 months range. What’s becoming probably more important than our own lead time is really customer preparedness. Especially now that we start to enter into these onshoring projects more and more, we will see probably very different cases where people already have brownfield or people need to build everything from scratch. This is what we don’t control fully, where our lead time might be absolutely enabling us to recognize those revenues this year.

It might well be that those sites are only ready by mid-2027 or even maybe second half of 2027 or so. As you know, when I mentioned about the Blockbuster we had, we won 2 years ago now on ATF, I mean, it’s a specific example where the customer site is still just being finalized right now. What we don’t control fully is customer preparedness, and especially with onshoring, that’s something we’re all gonna have to figuring out better in the upcoming few quarters here.

Casey Woodring, Analyst, J.P. Morgan1: Thanks. Appreciate it.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Matthew Hewitt with Craig-Hallum Capital Group. Matt, your line is open. Please go ahead.

Matthew Hewitt, Analyst, Craig-Hallum Capital Group: Good morning, and great start to the year. You know, analytics is becoming a much bigger demand area for your customers, whether it’s the CDMOs or the pharma companies. You’re seeing increased demand. You’re speaking to some of the growth that you’re seeing there. From an investment standpoint, where do you see opportunities to invest in that area, whether it’s, you know, real-time monitoring or, you know, taking some of the data that you’re capturing and kinda helping your customers identify areas for improvement? Is this an area that you’re investing internally? Is it an area that you see from an M&A perspective, maybe augmenting some of your existing capabilities? Any discussion there? Thanks.

Casey Woodring, Analyst, J.P. Morgan2: Yeah, Matt. Yeah, great question. I mean, obviously, as you mentioned, we’re really excited about the traction we’re seeing on process analytics. I mean, 50% growth in quarter one, 40% organic, really downstream analytics. I mean, we’ve never seen that before. In fact, historically, quarter one was always the weakest quarter from a seasonality point of view. That was really obviously an incredible performance. You’re asking absolutely the right question, what are we doing to make sure we capitalize on that, and we even can double down on that over the next several years? First of all, as you know, we said that upgrade cycle is just still at the beginning. That’s gonna be tailwind for us for the next several quarters, if not probably several years.

Beyond that, I didn’t talk so much about the PAT side. PAT has got huge traction as well. As you know, we launched our FlowVPX inline protein concentration technology 1.5 years, 2 years ago or so, which has got incredible traction while working on multiple other PAT technologies, product upgrade or product launches that will happen over the next 1-2 years. Talking about investment, talking about organic investment, we’re investing a huge amount of money on the R&D side to make sure we’ve got many more products on our shelves over the next several years. Both from an at-line but also from an in-line point of view, you’ll hear us talking about that massively over the next several quarters and years.

Then, yes, in term of M&A, absolutely. I mean, as is, you know, capital spending, top priority number one for us is on M&A side. I mean, we landed quarter one with $785 million of dry powder. We are looking at several opportunities. If the right opportunity comes on the analytics side to complement our offering further and so on, we would be very interested. The last piece I would mention. Services are benefiting from that greatly as well. I mean, our service business grew more than 30% in quarter one. The good news is we’ve got a very nice attachment rate of service to our analytical equipment.

That’s another area we’re investing into quite a bit, and then partially for that piece that is linked to the analytical business here.

Matthew Hewitt, Analyst, Craig-Hallum Capital Group: Thank you.

Casey Woodring, Analyst, J.P. Morgan3: Your next question comes from the line of Justin Bowers from Deutsche Bank. Justin, your line is open. Please go ahead.

Justin Bowers, Analyst, Deutsche Bank: Morning, everyone. It’s Deutsche Bank. I’ll squeeze a multi-parter into one. On the proteins, pretty strong quarter, especially against a tough comp. Can you talk about some of the drivers there? Is that more of a shorter cycle business? i.e., how much visibility do you have into that? Over the next two to three years, is that a franchise that you believe can continue to grow above fleet average?

Casey Woodring, Analyst, J.P. Morgan2: Hey, Justin, good morning. Happy to have a question on protein because that’s another business that I’m so happy about, the progress we’re seeing here. Yes, you’re right. I mean, meeting growth, lapping on what was a very strong quarter one 2025 was a really great positive surprise for us. Honestly, we got good demand across all our offering, but particularly on the ligand side. I mean, I mentioned in the past we’ve really become closer and closer with Purolite. We work really very much hand-in-hand together. They have fantastic traction, and we’re very happy about the way we collaborate together. That has been, well, one of the reason why protein did so well.

We’re in the long-term type of business here because beyond that specific collaboration, the fact also we have our destiny in our hands for all of the non-monoclonal antibody side of the business is also very encouraging because we are winning multiple, and when I say multiple, it’s really multiple designing. It’s a business that takes a little bit of time because where you first need to get designing and then you start to deliver some first pilot quantities. Hopefully some of these products are either making it to the market or if they are already on the market, our customers are gonna pull the trigger to switch from one supplier to us.

With all of the designing we’ve been working on, and we’ve got a dedicated team now that is going on the market, getting fantastic response from the market because they’ve never seen a company capable to develop a new ligand in 3 months and a new resin in 6 months. I’m absolutely very bullish about that market for the next several years. I think the best is still to come here for sure.

Justin Bowers, Analyst, Deutsche Bank: Thank you.

Casey Woodring, Analyst, J.P. Morgan3: We have reached the end of the Q&A session. I will now turn the call back to Olivier Loeillot for closing remarks.

Casey Woodring, Analyst, J.P. Morgan2: Okay. Thank you all for joining our call today. We had a very great first quarter, and we’re executing against the plan we’ve outlined, which is outpacing market growth, delivering margin expansion, and Jason gave you a good number of details about what we are achieving on that side, and finally making tangible progress on our strategies. I really want to thank all of our Repligen teammates. We have an incredible team, and we’re delivering a fantastic start of the year and looking forward to talking to you again in a quarter from now. Thank you all.

Casey Woodring, Analyst, J.P. Morgan3: This concludes today’s call. Thank you for attending. You may now disconnect.